Kolltan Pharmaceuticals (New Haven, CT) Elm Street participated in the Series A preferred stock financing of the company in May of 2009. Kolltan is developing anti-cancer therapeutics targeting receptor tyrosine kinases (RTKs) identified in the lab of Dr. Joseph Schlessinger, chair of Pharmacology at Yale. Dr. Schlessinger’s previously co-founded SUGEN and Plexxikon. Co-investors in the Series A financing include a large European venture fund. www.kolltan.com